Galectin-10 antibodies

US11066473B2 · kind B2 · utility

Assignees

• ARGENX IIP BV · BE
• VIB VZW · BE
• UNIVERSITEIT GENT · BE

Inventors

• Jean-Michel PERCIER · Wondelgem, BE
• Christophe Blanchetot · Laarne, BE
• Michael John Scott Saunders · Wondelgem, BE
• Hans De Haard · Oudelande, NL
• Sebastian Van Der Woning · Deinze, BE
• Emma Persson · Sint-Andries, BE
• Bart Lambrecht · Evergem, BE
• Savvas Savvides · Wondelgem, BE
• Hamida Hammad · Oudenaarde, BE
• Kenneth Verstraete · Evergem, BE

Key dates

• Filing date: Apr 12, 2019
• Grant date: Jul 20, 2021
• Expiry date: Apr 12, 2039

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/4724
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).